Dirk Schneider
Medical Science Liaison (MSL) in Germany
I felt a warm welcome from all at Oncopeptides, supporting each other is not only a word, but also true. And everyone is devoted – to the company, the product, and the patients.
I have spent many years working with multiple myeloma and have established a large network of customers. I want to contribute in making Oncopeptides known and ensuring that melflufen becomes a particularly important drug for patients who need a new option that can provide tumor control and maintained quality of life. I will combine my scientific expertise with my account management experience in the interaction with physicians. Failure is not an option for me, when I am convinced that my drug is a good one, I cannot accept that customers and patients shouldn’t benefit from it.